Table 5. Completed c10.5732/cjc.014.10289linical trials of Akt inhibitors in OC.

Phase	Treatment	No. of OC patients	Selected toxicities	Efficacy	Reference
I	Perifosine (MTD = 150 mg/day) + docetaxel	21	Nausea, vomiting, anorexia, and fatigue	At MTD in 11 patients, PR in 1 PTEN-null patient, SD in 3 patients	Fu et al.[37]
I	GSK795 (25, 50, or 75 mg/day)	12	Grade 2 anorexia (18%) and vomiting (18%)	2 (16%) cases of SD for 6 months with tumor shrinkage of 26% and 11%, respectively	Gungor et al.[38]
I	GSK211 (50-150 mg/day) + carboplatin (AUC = 5) + paclitaxel (175 mg/m2)	29	Grade 1/2 diarrhea, nausea, and fatigue	All patients in dose escalation: ORR = 30%; At MTD: ORR = 50%	Blagden et al.[39]

MTD, maximal tolerated dose; AUC, area under curve; SD, stable disease; ORR, objective response rate.